PXH Stock Overview
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Pixium Vision SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.25 |
52 Week High | €7.55 |
52 Week Low | €0.041 |
Beta | 0.95 |
1 Month Change | -32.80% |
3 Month Change | 400.00% |
1 Year Change | -85.84% |
3 Year Change | -99.73% |
5 Year Change | -99.69% |
Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
PXH | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0% | -0.6% | 1.6% |
1Y | -85.8% | 2.8% | 6.4% |
Return vs Industry: PXH underperformed the German Medical Equipment industry which returned 6.8% over the past year.
Return vs Market: PXH underperformed the German Market which returned 0.4% over the past year.
Price Volatility
PXH volatility | |
---|---|
PXH Average Weekly Movement | 91.4% |
Medical Equipment Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PXH's share price has been volatile over the past 3 months.
Volatility Over Time: PXH's weekly volatility has decreased from 170% to 91% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 40 | Lloyd Diamond | https://www.pixium-vision.com |
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh.
Pixium Vision SA Fundamentals Summary
PXH fundamental statistics | |
---|---|
Market cap | €1.53m |
Earnings (TTM) | -€10.52m |
Revenue (TTM) | €1.80m |
0.9x
P/S Ratio-0.1x
P/E RatioIs PXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PXH income statement (TTM) | |
---|---|
Revenue | €1.80m |
Cost of Revenue | €0 |
Gross Profit | €1.80m |
Other Expenses | €12.32m |
Earnings | -€10.52m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.58 |
Gross Margin | 100.00% |
Net Profit Margin | -584.66% |
Debt/Equity Ratio | -127.5% |
How did PXH perform over the long term?
See historical performance and comparison